Improvest® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Improvest®

Active ingredient

Gonadotropin Releasing Factor – Diphtheria Toxoid conjugate

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

April 13, 2022

Adverse event reports

Source: openFDA VeDDRA

150

Reports mentioning this ingredient

March 14, 2012 – June 5, 2025

106

Classified serious

per reporter assessment

10

Lack of expected efficacy

resistance signal

3

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “GONADOTROPIN RELEASING FACTOR (GNRF) - DIPHTHERIA TOXOID CONJUGATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Anaphylaxis	63
Anaphylactoid reaction	28
Death	13
Anaphylactic-type reaction	10
Sudden death	9
Closure, Abnormal	9
Dyspnoea	6
Lack of efficacy - NOS	6
INEFFECTIVE, STERILIZATION	4
Accidental exposure	3
Lethargy (see also Central nervous system depression in 'Neurological')	3
Death by euthanasia	3
Injection site inflammation	3
Injection site reaction NOS	3
Injection site swelling	3
Reddening of the skin	2
Uncoded sign	2
Color, Abnormal	2
Cyanosis	2
Anaphylactic shock	2

Species affected

Source: openFDA VeDDRA

Pig 126 Human 8 Bat 2 Horse 2

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient